← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 21.4% to $109.8M, while Net income decreased 21.0% to ($153.5M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $109.8MWatch
- Profitability — Net income ($153.5M)Watch
- Cash generation — Free cash flow ($162.7M)Note
- Accounting — Formula distress score · manipulation flag raised · earnings quality greyWatch
- Insiders — 0 buys; 7 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
UroGen Pharma Ltd.: Our approved products Jelmyto (mitomycin) for pyelocalyceal solution and Zusduri (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer ("low-grade UTUC") and recurrent low-grade intermediate risk non-muscle invasive bladder cancer ("low-grade intermediate risk NMIBC"), respectively.
Where the revenue comes from
Fiscal 2025, as UroGen Pharma Ltd. reports it. History and quarterly detail are in the app.
- Jelmyto$94.0M
- Zusduri$15.8M
Leadership changes
From UroGen Pharma Ltd.'s own filings, the day they're filed.
- Don Kim · Chief Financial Officer · departureeff. 2024-10-08
- Christopher Degnan · Chief Financial Officer · appointmenteff. 2024-10-07
- Fred E. Cohen · director · departureeff. 2024-09-12
Latest filings
- 8-K · Company announcement2026-08-20
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-23
- 8-K · Company announcement2026-06-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about UroGen Pharma Ltd., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.